ASCO® Genitourinary Cancers Symposium 2023

Enfortumab Vedotin | Urothelial Cancer | Abstract #439

Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the Phase 1b/2 EV-103 Cohort K study

Enfortumab Vedotin | Urothelial Cancer | Abstract #499

Enfortumab vedotin (EV) alone or in combination w/ pembrolizumab (P) in previously untreated cisplatin-ineligible patients w/ locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 Cohort K

Urothelial Carcinoma | Abstract #492

Understanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: A qualitative interview study with patients, caregivers, and physicians

Enfortumab Vedotin | Bladder Cancer | Abstract #TPS582

Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC) (Trial in Progress)

Enfortumab Vedotin | Bladder Cancer | Abstract #TPS585

Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)

Enfortumab Vedotin | Bladder Cancer | Abstract #TPS588

Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304

Tucatinib | Urothelial Cancer | Abstract #TPS587

A Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: urothelial cancer cohort (Trial in Progress)

Disitamab Vedotin | Urothelial Carcinoma | Abstract #TPS594

Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001, trial in progress)

Urothelial Carcinoma | Abstract #556

Systematic literature review and testing of HER2 status in urothelial carcinoma (UC)